Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms

Clin Exp Allergy. 2008 Jun;38(6):947-56. doi: 10.1111/j.1365-2222.2008.02990.x.

Abstract

Background: Histamine H1-receptor antagonists are used to relieve the symptoms of an immediate allergic reaction. They have additional anti-inflammatory effects that could result from an inhibition of the transcription factors activator protein-1 (AP-1) and nuclear factor-kappa B (NF-kappaB). The implication of the H1-receptor in these effects is controversial. Diphenhydramine is a first-generation H1-receptor antagonist while mizolastine and desloratadine are second-generation compounds. Mizolastine is also an inhibitor of 5-lipoxygenase (5-LO), an enzyme that has been involved in NF-kappaB activation.

Objective: We measured the ability of antihistamines to reverse histamine-induced smooth muscle contraction, an effect that involves the H1-receptor. We then investigated whether these drugs affect NF-kappaB and AP-1 activities in A549 lung epithelial cells, and whether this potential regulation involves H1-receptor and 5-LO.

Methods: Muscle tone was measured on tracheal segments of guinea-pigs. The H1-receptor was overexpressed by transfection and detected by Western blotting and immunofluorescence microscopy. NF-kappaB and AP-1 activities were assessed by reporter gene assays in cells overexpressing or not overexpressing the H1-receptor. Production of regulated upon activation, normal T cell expressed andsecreted (RANTES), a chemokine whose expression is induced through NF-kappaB, was measured using an immunoassay.

Results: H1-receptor antagonists reversed histamine-induced contraction in a dose-dependent manner. Induction of AP-1 and NF-kappaB activities by histamine and the down-regulatory effect of antihistamines required overexpression of the H1-receptor. In contrast, when tumour necrosis factor-alpha and a phorbol ester were used to stimulate NF-kappaB and AP-1 activities, respectively, repression of these activities did not involve the H1-receptor. Indeed, repression was triggered only by a subset of H1-receptor antagonists and was not stronger after overexpression of the H1-receptor. Mizolastine and desloratadine dose-dependently decreased tumour necrosis factor-alpha-induced production of RANTES. Diphenhydramine, H2- and H3-receptor antagonists as well as selective inhibitors of 5-LO were ineffective in this assay.

Conclusion: Repression of NF-kappaB and AP-1 activities by H1-receptor antagonists involves H1-receptor-dependent and -independent mechanisms but not 5-LO.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Animals
  • Arachidonate 5-Lipoxygenase / metabolism
  • Cell Line
  • Chemokine CCL5 / metabolism
  • Epithelial Cells / drug effects
  • Epithelial Cells / metabolism
  • Genetic Techniques
  • Guinea Pigs
  • Histamine / pharmacology
  • Histamine H1 Antagonists / pharmacology*
  • Humans
  • Lipoxygenase Inhibitors / pharmacology
  • Lung / cytology
  • Lung / drug effects
  • Lung / metabolism
  • Male
  • Muscle, Smooth / drug effects
  • NF-kappa B / metabolism*
  • Plasmids / genetics
  • Receptors, Histamine H1 / genetics
  • Receptors, Histamine H1 / metabolism*
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / metabolism
  • Tetradecanoylphorbol Acetate / pharmacology
  • Trachea / drug effects
  • Transcription Factor AP-1 / metabolism*
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Chemokine CCL5
  • Histamine H1 Antagonists
  • Lipoxygenase Inhibitors
  • NF-kappa B
  • Receptors, Histamine H1
  • Transcription Factor AP-1
  • Tumor Necrosis Factor-alpha
  • Histamine
  • Arachidonate 5-Lipoxygenase
  • Tetradecanoylphorbol Acetate